SCFD2
Sec1 family domain-containing protein 2
Also known as: FLJ39514, SCFD2_HUMAN, STXBP1L1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q8WU76
- Gene
- SCFD2
- Ensembl
- ENSG00000184178
- Chromosome
- 4
- Canonical length
- 684 aa
- Protein class
- Plasma proteins, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm
OverviewNCBI Gene
Predicted to be involved in intracellular protein transport and vesicle-mediated transport. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
684 residues, UniProt reviewed canonical sequence.
>Q8WU76|SCFD2
1 MSASGVLSFT QQGWEQVLAK VKRAVVYLDA ACAESLHWGC GSTRLLEAVG GPDCHLREFE
61 PDAIGGGAKQ PKAVFVLSCL LKGRTVEILR DIICRSHFQY CVVVTTVSHA VHLTANHVPA
121 AAAAEMEGQQ PVFEQLEEKL CEWMGNMNYT AEVFHVPLLL APVAPHFALT PAFASLFPLL
181 PQDVHLLNSA RPDKRKLGSL GDVDSTTLTP ELLLQIRCLV SGLSSLCEHL GVREECFAVG
241 SLSQVIAADL ANYAPAKNRK KTAAGRASVV FVDRTLDLTG AVGHHGDNLV EKIISALPQL
301 PGHTNDVMVN MIALTALHTE EENYNVVAPG CLSQSSDTTA KALWEALLNT KHKEAVMEVR
361 RHLVEAASRE NLPIKMSMGR VTPGQLMSYI QLFKNNLKAL MNHCGLLQLG LATAQTLKHP
421 QTAKWDNFLA FERLLLQSIG ESAMSVVLNQ LLPMIKPVTQ RTNEDYSPEE LLILLIYIYS
481 VTGELTVDKD LCEAEEKVKK ALAQVFCEES GLSPLLQKIT DWDSSINLTF HKSKIAVDEL
541 FTSLRDIAGA RSLLKQFKSV YVPGNHTHQA SYKPLLKQVV EEIFHPERPD SVDIEHMSSG
601 LTDLLKTGFS MFMKVSRPHP SDYPLLILFV VGGVTVSEVK MVKDLVASLK PGTQVIVLST
661 RLLKPLNIPE LLFATDRLHP DLGFLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SCFD2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.23
- Highest tissue expression
- 8.2 nTPM
Expression across tissuesHPA
Tissue
- adrenal gland: 8.2 nTPM
- cerebral cortex: 8.2 nTPM
- esophagus: 7.8 nTPM
- tonsil: 7.4 nTPM
- smooth muscle: 7 nTPM
- skeletal muscle: 6.9 nTPM
Single-cell type
- thymocytes: 313 nCPM
- oligodendrocyte progenitor cells: 271 nCPM
- megakaryocyte progenitors: 269 nCPM
- somatotrophs: 261 nCPM
- lactotrophs: 244 nCPM
- megakaryocyte-erythroid progenitors: 244 nCPM
Immune cell
- myeloid DC: 19 nTPM
- NK-cell: 18 nTPM
- non-classical monocyte: 13 nTPM
- plasmacytoid DC: 13 nTPM
- intermediate monocyte: 12 nTPM
- total PBMC: 11 nTPM
Brain region
- white matter: 19 nTPM
- hypothalamus: 18 nTPM
- pons: 18 nTPM
- medulla oblongata: 18 nTPM
- thalamus: 18 nTPM
- cerebral cortex: 17 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about SCFD2.
Disease | GeneticClinVar
1 pathogenic / likely-pathogenic of 109 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.22
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.22
- DepMap mean gene effect
- -0.12
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of SCFD2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SCFD2 as an antibody target. Whether an autoantibody or antibody against SCFD2 could matter depends on whether native SCFD2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SCFD2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label SCFD2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...